Okumura M, Okuda T, Nakamura T, Yajima M
Pharmacology Laboratories, Central Research Laboratories, Kaken Pharmaceutical Co., Ltd., Japan.
Biol Pharm Bull. 1996 Apr;19(4):530-5. doi: 10.1248/bpb.19.530.
We studied the effect of recombinant human basic fibroblast growth factor (bFGF) on wound healing in genetically diabetic mice. Wound closure after full-thickness excision of skin was markedly delayed in diabetic mice compared to normoglycemic mice. A single application of bFGF caused a marked acceleration of wound healing in a dose-dependent manner. There were no hypertrophic scars or unlimited granulation tissue formation in regenerated tissues treated with any doses of bFGF under histological examination. The repeated application of bFGF for 7 d showed a bell-shaped dose-response in the rate of wound closure, and the optimal dose was as small as 0.2-2 mu g per wound. Reduced angiogenesis and granulation tissue formation were observed in diabetic mice compared to normal mice, and bFGF treatment restored both responses to significant levels. The beneficial effect of bFGF on wound healing would be largely explained by enhanced angiogenesis and granulation tissue formation.
我们研究了重组人碱性成纤维细胞生长因子（bFGF）对遗传性糖尿病小鼠伤口愈合的影响。与血糖正常的小鼠相比，糖尿病小鼠全层皮肤切除后的伤口闭合明显延迟。单次应用bFGF可显著加速伤口愈合，且呈剂量依赖性。在组织学检查中，用任何剂量的bFGF处理的再生组织中均未出现肥厚性瘢痕或无限制的肉芽组织形成。连续7天重复应用bFGF在伤口闭合率方面呈现钟形剂量反应，最佳剂量低至每个伤口0.2 - 2μg。与正常小鼠相比，糖尿病小鼠的血管生成和肉芽组织形成减少，而bFGF治疗可将这两种反应恢复到显著水平。bFGF对伤口愈合的有益作用很大程度上可通过增强血管生成和肉芽组织形成来解释。
